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Abstract
Intravesical botulinum toxin A (BoNT-A) injection is effective in treating 
overactive bladder (OAB) and detrusor overactivity (DO)-induced inconti-
nence refractory to antimuscarinic treatment. In the past 5 years, there 
have been several clinical trials using BoNT-A targeting OAB and idiopathic 
DO (IDO), and the therapeutic results are promising. Recent investiga-
tions have shown that urothelial dysfunction and abnormality of sensory 
receptor expression or transmitter release in the suburothelial nerves 
might contribute to OAB refractory to antimuscarinics. Intravesical BoNT-A 
treatment to inhibit abnormal receptor expression or transmitter release 
in the sensory nerve terminals in the suburothelial space has shown to 
have a good therapeutic effect on OAB. Intradetrusor or suburothelial 
BoNT-A injections, with small or large doses of BoNT-A in the bladder 
body or bladder base, can achieve satisfactory results. However, BoNT-A 
impairs detrusor contractility and causes a large postvoid residual (PVR) 
urine volume after injection in some patients. This adverse effect induces 
acute urinary retention and it is difficult to empty the bladder in the early 
postoperative period. Urinary tract infections can occur in patients with a 
large PVR. Although adverse effects may not influence the therapeutic 
outcome, they might prohibit wide application of BoNT-A in the treatment 
of refractory OAB. Patients with a high risk of a large PVR or urinary reten-
tion should be taught clean intermittent catheterization. Analysis of 
patient characteristics and urodynamic variables has shown that patients 
who are elderly, have low detrusor contractility at baseline, and have 
chronic medical diseases are at risk of adverse effects. Therefore, careful 
adjustment of the dose, appropriate injection site and correct patient 
selection is mandatory to achieve satisfactory results with intravesical 
BoNT-A therapy. [Tzu Chi Med J 2009;21(4):277–284]
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1. Introduction
Overactive bladder (OAB) is a syndrome character-
ized by urgency frequency with or without urgency 
incontinence. Usually no metabolic or anatomical dis-
orders can be found [1]. OAB symptoms have a sig-
nificant impact on the emotional wellbeing and quality 
of life of those affected [2]. Although there are sev-
eral new therapeutic options with promising treatment 
outcomes, antimuscarinic drugs remain the first-line 
treatment and clinical effects with good tolerability 
have been confirmed. However, not all OAB patients 
benefit from antimuscarinic agents [3], and adverse 
effects such as dizziness, dry mouth, blurred vision, 
and constipation, are intolerable for some patients 
[4]. Intravesical botulinum toxin (BoNT) injections 
provide an alternative treatment with favorable effi-
cacy for these patients.
BoNT was first used in treating strabismus based 
on the mechanism that it can inhibit signal transmis-
sion at the neuromuscular and neuroglandular junc-
tions by binding to the synaptic vesicle protein SV2 
during neurotransmitter exocytosis when more ac-
tive receptors are exposed [5]. The application of 
BoNT-A for the treatment of lower urinary tract symp-
toms was initiated in the late 1980s. Dykstra et al 
described injection of BoNT-A into the external ure-
thral sphincter in spinal cord injured (SCI) patients 
to induce chemical sphincterotomy and to lower de-
trusor-sphincter dyssynergia [6]. Since the detrusor 
contraction is mediated by acetylcholine (ACh) para-
sympathetic innervation, Schurch et al successfully 
treated SCI patients with neurogenic overactivity in-
continence using detrusor BoNT-A injections at mul-
tiple sites [7]. A large scale multicenter trial also 
confirmed that BoNT-A detrusor injection significantly 
improved urinary incontinence associated with health-
related quality of life in patients with neurogenic 
urinary incontinence [8].
BoNT-A can cause muscle paralysis by blocking 
ACh release at the neuromuscular junction [9]. Re-
duction of expression of purinergic receptor P2X3 
and transient receptor potential vanilloid receptor 
subfamily 1 on suburothelial sensory fibers has been 
observed in patients receiving detrusor BoNT-A in-
jections for detrusor overactivity (DO) and has been 
associated with reduction in the degree of urgency in 
patients with successful therapeutic results [10]. 
Nociceptive sensory fibers and stretch sensing fibers 
are abundant in the suburothelial space [11,12]. 
An antinociceptive effect through a direct decrease 
of neuropeptides, such as substance P and calci-
tonin gene-related peptide released from activated 
sensory neurons, accounts for the clinical effective-
ness of BoNT-A in pain relief [13,14]. Based on the 
pathophysiology of OAB and DO, BoNT has been en-
thusiastically applied in treating urinary urgency or 
incontinence refractory to antimuscarinics in recent 
years [15–43] (Table 1). Although promising therapeu-
tic effects have been confirmed in several case series 
and clinical trials, adverse events have been reported 
inconsistently. There is no consensus on the dose of 
BoNT-A or BoNT-B, injection sites, and the duration 
between repeat injections. This review attempts to 
analyze the clinical results of BoNT-A on OAB and 
idiopathic DO (IDO) and adverse effects that occur 
after BoNT-A injection. Doctors need to be aware of 
the adverse effects that might endanger the patient 
before injecting BoNT-A into the bladder.
2. Clinical effects of BoNT-A on DO
BoNT-A induces reduction of the urgency sensation 
in the first week after intravesical injection. In one 
study, significant improvement in urgency frequency, 
and nocturia were seen on day 2 and in urinary in-
continence on day 3 in patients with neurogenic DO, 
with significant changes in OAB on day 4 in patients 
with IDO [35]. Clinical observation also found that 
acute urinary retention may occur as early as the first 
day after treatment [18]. A large postvoid residual 
(PVR) urine volume can develop during the first month 
and decrease slowly with time [31]. In one study, uri-
nary incontinence disappeared within 1–2 weeks 
after injection [25].
At first, most investigators used detrusor injec-
tions of 200 U or 300 U of Botox (100 U/vial; Allergan, 
Irvine, CA, USA) to treat patients with IDO [15,16,18–
20,22,23]. The therapeutic results varied greatly. 
Kessler et al treated 11 patients with IDO with detru-
sor injections of 300 U Botox and the maximal blad-
der capacity increased from 220 to 340 mL. However, 
four patients needed clean intermittent catheteriza-
tion (CIC) due to a large PVR [16]. Rajkumar et al 
treated 15 IDO women with detrusor injections of 
300 U Botox and 14 had improvement in urgency 
and frequency. The therapeutic effects lasted for 5–6 
months [22]. Popat et al used 200 U for 31 IDO pa-
tients. Although significant improvement in bladder 
capacity was noted after treatment, 20% of the pa-
tients needed CIC [23]. Schulte-Baukloh et al used 
300 U for detrusor and urethral injections in seven 
women with OAB without DO. The bladder capacity 
increased by 20% and all patients could void without 
the need for CIC [19]. The dose of BoNT-A seems to 
have an effect on the continence rate after injection, 
but the incidence of adverse effects also increases. 
In the author’s previous study, detrusor injections of 
200 U provided a 73.3% success rate in 30 IDO pa-
tients, with a mean therapeutic duration of 5.3 months 
[15]. Further studies using suburothelial injections of 
Botox at a dose of 200 U demonstrated better thera-
peutic results (85% success rate) similar to those 
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 Dose & sites of Dysuria,  Large PVR,  Required CIC, 
  injection n (%) n (%) n (%)
Kuo (2004) [15] 18 IDO 200 U BTX-A 6 (33) 6 (33) 4 (22)
   Detrusor ˜  40
Kessler et al (2005) [16] 11 IDO 300 U BTX-A 4 (36) 4 (36) 4 (36)
   Detrusor ˜  30
Werner et al (2005) [17] 26 IDO women 100 U BTX-A 1 (4) 2 (8) 2 (8)
   Detrusor ˜  30
Kuo (2005) [18] 20 IDO 200 U BTX-A 15 (75) 7 (35) 6 (30)
   Suburothelium ˜  40
Schulte-Baukloh et al 7 OAB 300 U BTX-A NA 0 0
 (2005) [19]   Detrusor ˜  30 and/or
   urethral 50–75 U
Schulte-Baukloh et al 38 OAB 200–300 U BTX-A NA 0 0
 (2005) [20]   Detrusor ˜  40–50
Ghei et al (2005) [21] 20 IDO 5000 U BTX-B 2 (10) 2 (10) 2 (10)
   Detrusor ˜  10
Rajkumar et al (2005) [22] 15 IDO 300 U BTX-A NA 7 (47) 0
   Detrusor ˜  30
Popat et al (2005) [23] 31 IDO 200 U BTX-A NA 2 (6.4) 6 (19.3)
   Detrusor ˜  20
Kuo (2006) [24] 35 IDO, 40 NDO 100 U BTX-A 13 (52) 8 (32) 0
   150 U BTX-A 19 (76) 13 (52) 2 (8)
   200 U BTX-A 19 (76) 18 (72) 6 (24)
   Suburothelium ˜  40
Schmid et al (2006) [25] 100 IDO 100 U BTX-A NA NA 4 (4)
   Detrusor ˜  30
Lucioni et al (2006) [26] 40 OAB Trigone ˜  24 NA NA NA
   Detrusor ˜  16
Hoebeke et al 15 OAB children 100 U BTX-A 4 (27) 1 (7) 0
 (2006) [27]   Detrusor
Kalsi et al (2006) [28] 16 IDO 200 U BTX-A NA NA 2 (12.5)
   Detrusor ˜  20
Hirst et al (2007) [29] 20 IDO 5000 U BTX-B NA NA 1 (5)
   Detrusor ˜  20
Ghalayini & Al-Ghazo 16 IDO 500 U Dysport NA NA 3 (19)
 (2007) [30]   Detrusor
Sahai et al (2007) [31] 16 IDO 200 U BTX-A NA 7 (44) 6 (37.5)
   Detrusor ˜  20
Kuo (2007) [32] 45 IDO 100 U BTX-A
   Detrusor (n = 15) 5 (33) 5 (33) 2 (13)
   Suburothelium (n = 15) 7 (47) 7 (47) 2 (13)
   Bladder base (n = 15) 2 (13) 2 (13) 0
Jeffery et al (2007) [33] 25 IDO 500 U Dysport NA NA 8 (36)
   Detrusor ˜  20
Karsenty et al (2007) [34] 12 IDO 200 U BTX-A 0 0 0
   Trigone ˜  10
Kalsi et al (2008) [35] 8 IDO 200 U BTX-A NA NA 0
Kuschel et al (2008) [36] 26 IDO 100 U BTX-A NA 1 (4) 1 (4)
   Detrusor
Brubaker et al 28 IDO 200 U BTX-A NA 12 (43) 12 (43)
 (2008) [37]   Detrusor ˜  20
White et al (2008) [38] 14 IDO > 75 yr 200 U BTX-A NA 2 (10) 0
   Detrusor ˜  20
Khan et al (2009) [39] 81 IDO 200 U BTX-A NA 35 (43) 31 (38)
   Detrusor ˜  20
Cohen et al (2009) [40] 44 OAB 100 U BTX-A (n = 20) NA NA 1 (5)
   150 U BTX-A (n = 24)   1 (4)
   Detrusor ˜  10–15
Sahai et al (2009) [41] 67 IDO 200 U BTX-A NA NA 19 (29)
   Detrusor ˜  20
Flynn et al (2009) [42] 15 OAB 100 U BTX-A NA 4 (26) 1 (7)
   200 U BTX-A
Kessler et al (2009) [43] 67 OAB women 200 U BTX-A NA 28 (43) 28 (43)
PVR = postvoid residual; CIC = clean intermittent catheterization; IDO = idiopathic detrusor overactivity; BTX-A = botulinum toxin type A; OAB = over-
active bladder; NA = not available; NDO = neurogenic detrusor overactivity; BTX-B = botulinum toxin type B.
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achieved with 300 U in other studies [16,19,22]. How-
ever, there was a higher incidence of adverse effects 
such as difficult urination (75%), a large PVR (35%) 
and need for CIC (30%) [18].
Ghei et al tested the efficacy and safety of BoNT-B 
for treatment of OAB in a randomized, double-blind, 
placebo-controlled crossover trial. There were statis-
tically significant paired differences in the changes in 
average voided volume, urinary frequency and epi-
sodes of incontinence between active treatment and 
placebo as well as change in the quality of life evalu-
ated by King’s Health Questionnaire. However, auto-
nomic side effects were observed in four patients [21].
Sahai et al performed a double-blind, placebo-
controlled trial. They randomized participants to in-
tradetrusor injections of 200 U Botox or a placebo. 
Significant increases in maximum cystometric capac-
ity were observed at 4 weeks and 12 weeks in treated 
patients compared with those given the placebo. Botox 
reduced frequency and urgency urinary incontinence 
episodes at 4 and 12 weeks, respectively. Urgency 
was reduced at 4 weeks in the BoNT-A group. The 
PVR increased at 4 weeks in 44% of patients who 
received BoNT-A injections, but this was insignificant 
by 12 weeks. Of these patients, 37.5% required CIC. 
Significant improvement in the quality of life was ob-
served following BoNT-A treatment. An extension study 
suggested that the beneficial effects of BoNT-A were 
maintained for at least 24 weeks [31].
Brubaker et al compared 200 U intradetrusor Botox 
versus a placebo in women with refractory idiopathic 
urge incontinence. Approximately 60% of the treated 
women had a clinical response based on the Patient 
Global Impression of Improvement [37]. The median 
duration of their responses was 373 days, significantly 
longer than the ≤ 62 days for the placebo group. How-
ever, in the BoNT-A group, 43% of patients had an 
increased PVR and 75% of those with large PVRs had 
urinary tract infections (UTI). Because these adverse 
effects exceeded expected ranges, further injections 
were stopped after 43 patients were randomized: 28 
to the treatment group and 15 to the placebo group.
Based on these clinical trials, the efficacy of BoNT 
on OAB has been confirmed and BoNT-A has been 
recommended as an alternative for patients with 
OAB refractory to antimuscarinics or drug intolerance 
[44,45].
3. Dose of BoNT-A for OAB
Because of the high incidence of adverse events after 
BoNT-A injections, the dose of BoNT-A for IDO has 
been reduced to 100 U by many investigators and a 
satisfactory outcome can still be achieved. Werner 
et al treated 26 women with IDO with a 53% success 
rate [17]. Schmid et al treated 100 IDO patients with 
100 U BoNT-A and an 88% success rate was achieved 
[25]. However, the duration of therapeutic effects 
and incidence of adverse effects with 100 U BoNT-A 
need further clarification. A dose-related increase in 
adverse events has been found with increasing doses 
of Botox [24]. In a recent report by the author, 35% 
of patients had UTI, 30% had a large PVR requiring 
CIC, and 75% had difficult urination after suburothe-
lial injection of 200 U Botox [24]. This high incidence 
of adverse effects might prohibit patients receiving 
a second injection when OAB relapses. A dose of 
suburothelial Botox of 100 U can reduce the rates of 
UTI to 4.3%, a large PVR to 30.4%, and difficult uri-
nation to 56.5% [24]. Therefore, adjustment of the 
dose for IDO patients seems mandatory to minimize 
de novo adverse effects. A recent study comparing 
100 U versus 150 U Botox in patients with IDO also 
showed that symptom reduction and improvement in 
quality of life were equivalent [39]. Patients with IDO 
can increase bladder capacity without reducing void-
ing pressure and maximum flow rate, although PVR 
might be increased after intravesical injection of 
100 U BoNT-A [31].
4. Clinical effects of BoNT-A with 
different injection methods 
and sites
There is a consensus on the detrusor injection tech-
nique for neurogenic DO, but not for IDO or OAB [45]. 
Recently, studies of BoNT-A injection for OAB and IDO 
have used suburothelial instead of intradetrusor injec-
tions. The important point is to target the suburothe-
lial sensory pathway rather than paralysis of detrusor 
muscle contractility in the treatment of OAB. However, 
because the bladder wall is thin, it is impossible 
to differentiate the suburothelium from the detrusor 
layer on cystoscopy [46]. With regard to injections into 
the bladder wall, it is difficult to inject solely into the 
suburothelium without affecting detrusor contractility. 
A randomized trial comparing the effects of detrusor, 
suburothelial and bladder base injections of BoNT-A 
in IDO showed no significant difference between 
detrusor and suburothelial injections [31].
Desensitization of the mechanoreceptors of subu-
rothelial sensory fibers by BoNT-A can result in a 
decrease of bladder urgency sensation and reduced 
sensory neuropeptide-mediated DO. One important 
factor for a successful therapeutic outcome is an ac-
curate injection depth and adequate distribution of 
toxin into the suburothelial space or detrusor muscle. 
Because the bladder wall is very thin, the injection 
needle should not be inserted more than 1 mm or the 
solution might leak outside the detrusor wall. In a re-
cent study of the distribution of 300 U Botox for neu-
rogenic DO, magnetic resonance imaging detected 
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approximately 17.6% of the solution outside the blad-
der dome, with a mean 25–33% of the detrusor vol-
ume covered [47]. Injection into the suburothelium 
might avoid the potential loss of BoNT-A through 
detrusor injections, especially in the bladder of pa-
tients with IDO. If the toxin is not adequately dis-
tributed into the bladder wall, or is injected outside 
the bladder wall, the desired effect might not be 
achieved. This might explain why some studies found 
that detrusor injections of large doses of BoNT-A had 
therapeutic effects similar to those of suburothelial 
injections of small doses. It is possible that some 
detrusor injections were too deep and were outside 
the bladder wall.
The trigone and bladder base have abundant sen-
sory fibers. Injections of BoNT-A into these areas have 
therapeutic effects on idiopathic urgency frequency 
syndrome and interstitial cystitis [48]. Although the 
trigone is rich in sensory fibers, the role of these fi-
bers in bladder urgency sensation and IDO has not yet 
been established. Most urologists use a “trigone spar-
ing injection” technique, largely because of potential 
vesicoureteral reflux after BoNT-A. However, there 
has been no evidence of this to date [32,34]. An ad-
vantage of trigonal injections is that detrusor under-
activity does not develop after treatment, so a large 
PVR and acute urinary retention may not develop 
[32]. Another study evaluating the effects of BoNT-A 
injections in the trigone on the antireflux mechanism 
confirmed the safety in terms of development of 
vesicoureteral reflux or upper urinary tract damage 
[49]. Whether trigone and bladder base injections 
have this effect on OAB-dry or bladder hypersensitiv-
ity deserves further clinical study.
4.1. Adverse effects of intravesical BoNT-A 
injections
The main adverse effects of intravesical BoNT A injec-
tion are acute urinary retention, and a large PVR and 
UTI, which occur in variable percentages of patients 
[15–43]. UTI is usually associated with a large PVR 
[37]. Other adverse effects such as hematuria, mictu-
rition pain and general weakness are transient and 
are easily overcome by conventional treatment [18]. 
Intravesical injections of BoNT-A usually will not cause 
bleeding if the vessels of the bladder wall are avoided 
under direct visualization. A Foley catheter can be 
placed overnight or until the urine turns clear. The 
effects of BoNT-A appear on the second or third day, 
with a gradual increase in difficult urination and in-
complete emptying.
In a recent study, large PVRs requiring CIC occurred 
in 30% of patients treated with 200 U Botox. A lower 
Qmax, lower projected isovolumetric pressure and 
lower bladder contractility index are risk factors for 
incomplete emptying [41]. Although another study 
found injections of 200 U of Botox were safe in eld-
erly patients, the detrimental effect of retention on 
quality of life can be considerable [38]. Therefore, 
patients should be fully counseled on the risks of 
urinary retention and trained in intermittent cathe-
terization before the procedure [50]. If adverse ef-
fects occur, an indwelling Foley catheter or CIC should 
be used to avoid UTI or upper urinary tract damage. 
After the first month, difficult urination will resolve, 
with improvement in urinary incontinence, bladder 
pain and urgency symptoms [18,31]. Interestingly, 
the occurrence of acute urinary retention and a large 
PVR do not affect the success rate of BoNT-A for OAB. 
In an analysis of 65 women treated with 200 U BoNT-A 
detrusor injections, there was no significant difference 
in the success rate between those who did and those 
who did not use CIC for a large PVR. The institution 
of CIC for a large PVR does not impair the quality of 
life after BoNT-A injection [43].
The response rate of BoNT-A on DO is closely 
related to the dose. Detrusor injections of 200 U of 
BoNT-A yield a response duration of 12–15 months 
[31], whereas those of 100 U BoNT-A are approximately 
6 months [32,33]. However, the incidence of adverse 
effects is closely related to the dose [32]. In a ran-
domized trial of DO, the incidence of a large PVR was 
30%, 52% and 72% for 100 U, 150 U and 200 U BoNT, 
respectively [24]. Another recent clinical trial also 
found that the therapeutic efficacy was equivalent for 
100 U and 150 U BoNT-A detrusor injections for OAB. 
A dose as small as 100 U appears to be adequate for 
reducing OAB symptoms and avoiding adverse events 
[40]. Bladder base injection alone also results in a 
lower incidence of acute urinary retention, but this 
treatment modality has a significantly shorter thera-
peutic period than bladder body injection [32].
5. Risk factors for developing adverse 
events after BoNT-A injection
Although a large PVR, UTI and chronic urinary reten-
tion remain obstacles for the wide application of 
BoNT-A in treatment of refractory DO, no factors pre-
dicting these adverse effects have been found. Since 
major adverse effects are associated with decreased 
detrusor contractility after BoNT-A injection, it is ra-
tional to speculate that age, a large baseline PVR, pres-
ence of comorbidity and impaired baseline detrusor 
contractility might carry risks for large postoperative 
PVR. Elderly patients with comorbidity might have less 
whole body energy and reduced muscle power in the 
detrusor. Previous studies have shown that subu-
rothelial injections increase the risks for a high inci-
dence of adverse events, especially a large PVR and 
straining to void [18,32]. This may be attributed to 
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greatly impaired voiding efficiency because of im-
paired detrusor contractility through sensory dener-
vation after BoNT-A suburothelial injection. Thus, 
the dose for suburothelial BoNT-A injection may be 
reduced in vulnerable patients to prevent urinary 
retention or a large PVR after treatment.
Eleven previous clinical trials and reports of BoNT-A 
for OAB and IDO reported a 24–43% incidence of 
transient urinary retention requiring CIC [15,16,18, 
24,31,33,37,39,41,43] and 10 trials reported a 
32–72% incidence of a large PVR and difficulty in 
urination [15,16,18,22,24,31,32,37,39,43]. Although 
not all patients develop a large PVR or urinary reten-
tion, difficult urination and voiding by abdominal 
straining may be under-reported and might be poten-
tial problems after BoNT-A injection. However, pa-
tients with OAB and urinary incontinence (OAB-wet) 
might prefer these adverse effects to refractory uri-
nary incontinence.
Clinically, most patients with OAB are elderly and 
may have several other medical diseases. Although de-
trusor BoNT-A injection was found to be safe for eld-
erly patients with refractory OAB [15], the high rate 
of adverse effects deserves special attention before 
this treatment is recommended for patients with OAB 
and for those who are refractory to antimuscarinics. 
The risk factors for adverse effects should be deter-
mined before this novel treatment is accepted as the 
first-line treatment for refractory OAB.
Another interesting finding is the higher rate of UTI 
in women after BoNT-A injection, even though fewer 
women have acute urinary retention. Women are 
prone to develop UTI if they have a large PVR [37]. 
After BoNT-A injection, half of women have to void 
by abdominal straining and have a large PVR, which 
are risk factors for UTI in women. Men with benign 
prostatic hyperplasia (BPH) also have a higher risk of 
UTI than men who have undergone transurethral re-
section of the prostate for BPH. This may be attributed 
to a high voiding pressure and large PVR after BoNT-A 
injection. BPH also carries the risk of hematuria after 
BoNT-A injection. Therefore, in men with BPH, the in-
jection should be carefully carried out to avoid injury 
to the bladder base or prostatic urethra.
Treatment of idiopathic OAB is not similar to that 
for neurogenic DO. A good therapeutic result for neu-
rogenic DO is no incontinence and patients can ac-
cept the need for CIC to empty the bladder instead 
of urinary incontinence. However, patients with OAB 
need to be continent and able to void spontaneously 
without CIC or difficulty in urination after BoNT-A in-
jection. Patients with OAB might have unreasonably 
high expectations of the therapeutic results of BoNT-A 
treatment. Therefore, they may feel upset when a large 
PVR and difficulty in urination develop after BoNT-A 
injection. Thus, fully informed consent should be 
obtained preoperatively.
6. Conclusion
Intravesical BoNT-A injection has emerged as an ef-
fective treatment for DO incontinence refractory to 
antimuscarinic treatment. Reports from case series 
and clinical trials have demonstrated that BoNT-A can 
reduce urgency incontinence within 1–2 weeks and 
the effects can be maintained for 6–12 months, de-
pending on the dose. However, increasing doses can 
result in de novo problems such as a large PVR, tran-
sient urinary retention and UTI. To reduce the risk of 
adverse effects, careful selection of patients and ad-
justment of the dose and sites of BoNT-A injection 
are important. Patients who are older than 75 years 
and have impaired detrusor contractility, a large PVR, 
or chronic medical diseases are at significant risk 
of postoperative adverse effects. Therefore, fully in-
formed consent should be obtained and CIC should 
be taught in case adverse effects occur after BoNT-A 
injection. Nevertheless, institution of CIC within the 
first postoperative month does not impair the quality 
of life of patients after BoNT-A injection for OAB.
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